每经记者｜陈晴 每经编辑｜魏官红 并购重组 衢州发展：拟购买先导电科股份并募集配套资金 衢州发展公告，公司拟通过发行股份等方式购买广东先导稀材股份有限公司持有的先导电子科技股份有 限公司的股份，同时募集配套资金。本次交易正在筹划阶段，相关方案尚未最终确定。 *ST海华：控股子公司茫崖源鑫能源拟422.11万元收购若羌源鑫能源51%股权 *ST海华公告，控股子公司茫崖源鑫能源有限公司拟以现金422.11万元收购新疆庆源实业集团有限公司 持有的若羌源鑫能源有限公司51%股权。本次交易构成关联交易，但不构成重大资产重组。 中贝通信：终止控股子公司贝通信国际股权收购事项 中贝通信公告，公司控股子公司贝通信国际计划以自有资金2500万美元（折合人民币约1.82亿元）收购 PT.Semesta Energi Services 55%股权，但因未满足投资协议中约定的核心交割条件，经协商决定终止本 次收购事宜。此次终止不会对公司现有经营业绩及财务状况产生不利影响。 业绩披露 仕佳光子：2025年上半年归属于上市公司股东的净利润2.17亿元，同比增长1712% 仕佳光子公告，2025年上半年营业收入9.93亿元，同比增长121 ...

恩华药业（SZ 002262，收盘价：22.93元）7月29日晚间发布半年度业绩报告称，2025年上半年营业收 入约30.1亿元，同比增加8.93%；归属于上市公司股东的净利润约7亿元，同比增加11.38%；基本每股收 益0.69元，同比增加11.29%。 （文章来源：每日经济新闻） ...

Core Points - Enhua Pharmaceutical announced the approval of its 2025 semi-annual report and the conditions for the first unlock period of its 2024 restricted stock incentive plan [1] Group 1 - The seventh supervisory board of Enhua Pharmaceutical held its third meeting and reviewed the full text and summary of the 2025 semi-annual report [1] - The board also approved the proposal regarding the achievement of the unlock conditions for the first unlock period of the restricted stock incentive plan for 2024 [1]

重要公告： 药明康德：拟将回购股份价格上限调整为不超114.15元/股 *ST海华：控股子公司拟4300万元收购鲁新鼎盛100%股权 沪市重要公告： 药明康德：拟将回购股份价格上限调整为不超114.15元/股 药明康德(603259) 公告：拟将2025年第一次以集中竞价交易方式回购A股股份的回购股份价格上限由不 超过90.72元/股（含）调整为不超过114.15元/股，本次回购方案的其他内容不变。 *ST海华：控股子公司拟4300万元收购鲁新鼎盛100%股权 *ST海华(600243) 公告：基于巴州鲁新鼎盛燃气有限公司（下称："鲁新鼎盛"）所处的天然气行业和地 理位置具有良好的发展前景，公司控股子公司茫崖源鑫拟与徐海波、徐瑶瑶、鲁新鼎盛签署《收购协 议》，约定控股子公司茫崖源鑫以现金4300万元取得鲁新鼎盛100%的股权。 神马电力：拟以3亿元—4亿元回购股份 神马电力(603530) 公告：公司拟以3亿元—4亿元回购股份，拟全部用于公司股权激励及/或员工持股计 划，回购股份价格不超过38元/股。 仕佳光子：上半年净利润2.17亿元，同比增长1712% 滨化股份：筹划发行H股股份并在香港联交所上市事项 恩 ...

（编辑 任世碧） 证券日报网讯 7月29日晚间，恩华药业发布公告称，公司第七届董事会第三次会议审议通过了《公司 2025年半年度报告全文及摘要》《关于2024年限制性股票激励计划授予的限制性股票第一个解除限售期 解除限售条件成就的议案》。 ...

Core Viewpoint - Enhua Pharmaceutical reported continuous growth in its operating performance for the first half of 2025, with revenue reaching 3.01 billion yuan, an increase of 8.93% year-on-year, and a net profit attributable to shareholders of 700 million yuan, up 11.38% year-on-year [1] Financial Performance - The company achieved an operating revenue of 3.01 billion yuan, reflecting an 8.93% increase compared to the same period last year [1] - The net profit attributable to shareholders was 700 million yuan, marking an 11.38% year-on-year growth [1] - The net profit after deducting non-recurring gains and losses was 699 million yuan, which is a 10.33% increase year-on-year [1] R&D Investment - Enhua Pharmaceutical invested approximately 395 million yuan in research and development, representing a 23.97% increase compared to the previous year [2] - The company has over 70 ongoing research projects in the pipeline and holds the largest product line in the central nervous system drug sector in China [2] Innovative Drug Development - The company has 17 innovative drug projects under development, including 1 project in Phase III clinical trials and 2 projects in Phase II clinical trials [3] - Collaborations include partnerships with San Sheng Pharmaceutical and Harvard Medical School for various drug development projects [3] Digital Healthcare Development - Enhua Pharmaceutical has established a digital healthcare platform since 2015, which includes online consultation and health services, with over 70,000 registered doctors and more than 2 million patient visits annually [4] - The company has developed several digital mental health products, including AI-based psychological risk screening systems and virtual reality tools [4] Expansion and Partnerships - The company operates 25 psychological clinics and has signed contracts with over 400 corporate clients, covering nearly 2 million individuals [5] - Enhua Pharmaceutical is actively pursuing overseas listing plans to expand financing channels and support business growth [5]

Group 1 - Anhui Construction won a joint bid for the Chongqing Rongchang to Sichuan Zigong expressway project, with a total estimated investment of 3.614 billion yuan and a construction period of 3 years [1] - Hongfa Co. reported a net profit of 964 million yuan for the first half of 2025, a year-on-year increase of 14.19%, with revenue of 8.347 billion yuan, up 15.43% [1][2] - Lujiazui's net profit for the first half of 2025 was 815 million yuan, a decrease of 7.87%, despite a revenue increase of 33.91% to 6.598 billion yuan [3] - Enhua Pharmaceutical achieved a net profit of 700 million yuan, up 11.38%, with revenue of 3.010 billion yuan, an increase of 8.93% [4][5] - China CNR signed several major contracts totaling approximately 32.92 billion yuan, covering various sectors including urban rail vehicles and wind power equipment [6] - WanTong Intelligent signed an exclusive sales and cooperation agreement in the embodied intelligence field, gaining global sales rights for specific chip-based products [7][8] Group 2 - Liansheng Technology's subsidiary received a government subsidy of 13.5 million yuan, accounting for 12.24% of the company's latest audited net profit [9] - Guobang Pharmaceutical reported a net profit of 456 million yuan, a year-on-year increase of 12.60%, with revenue of 3.026 billion yuan, up 4.63% [10] - Baotai expects a net loss of 110 to 140 million yuan for the first half of 2025, a reduction in loss compared to the previous year [11] - Sains expects a net profit decrease of 57.53% to 60.13%, with projected revenue growth of 15.17% to 23.59% [12] - Nanya New Materials anticipates a net profit of 80 to 95 million yuan for the first half of 2025, an increase compared to the previous year [13] - Tian Pharmaceutical's subsidiary passed the consistency evaluation for a peritoneal dialysis solution [14] Group 3 - Shede Liquor announced the resignation of director Ni Qiang due to work reasons [15] - Greentown Water plans to transfer assets and liabilities of its ASEAN subsidiary to improve resource allocation [16] - Beibu Gulf Port's subsidiary signed an associated transaction contract worth 11.199 million yuan [17] - Beibu Gulf Port announced multiple resignations of directors and executives [18] - Jidian Co. reported the resignation of its deputy general manager due to work changes [19] - Wanhua Chemical's industrial park in Fujian resumed production after maintenance [20] Group 4 - Shanghai Pharmaceuticals received approval for a clinical trial of a new indication for its B019 injection [21] - Jianbang Co. reported a net profit of 69.66 million yuan, a decrease of 27.72%, with revenue of 307 million yuan, down 15.37% [23] - Jianbang Co. plans to use up to 400 million yuan of idle funds for cash management [25] - Wanfu Bio's subsidiary obtained multiple medical device registrations [28] - Hunan Tianyan announced a change in its controlling shareholder to China Chang'an Automobile Group [29][30] - Xizhuang Co. plans to establish a joint venture for sustainable aviation fuel [32]

Core Insights - Enhua Pharmaceutical (002262.SZ) reported a revenue of 3.01 billion yuan for the first half of 2025, representing a year-on-year growth of 8.93% [1] - The net profit attributable to shareholders was 700 million yuan, an increase of 11.38% year-on-year [1] - The basic earnings per share stood at 0.69 yuan [1] R&D Investment and Projects - The company has over 70 ongoing research projects with a research expenditure of 395 million yuan, reflecting a growth of 23.97% compared to the same period last year [2] - In the area of innovative drug development, there are currently 17 ongoing projects, including 1 project that has completed Phase III clinical trials and 2 projects that have completed Phase II trials [2] - The company is also engaged in 48 generic drug projects, with 1 project having received production approval and 5 projects currently under review for production [2]

Financial Performance - The company reported a revenue of 3.01 billion yuan for the first half of 2025, representing a year-on-year increase of 8.93% [1] - The net profit attributable to shareholders was 700 million yuan, showing a year-on-year growth of 11.38% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 699 million yuan, with a year-on-year increase of 10.33% [1] - The basic earnings per share were 0.69 yuan [1] Research and Development - The company has over 70 ongoing research projects, with a research expenditure of 395 million yuan, which is a 23.97% increase compared to the same period last year [2] - In the field of innovative drug development, there are currently 17 innovative drug projects under research, including 1 project that has completed Phase III clinical trials and 2 projects that have completed Phase II clinical trials [2] - The company is conducting 48 projects in generic drug development, with 1 project having received production approval and 5 projects currently under review for production approval [2]

Group 1 - The company reported a revenue of 3.01 billion yuan for the first half of 2025, representing a year-on-year growth of 8.93% [1] - The net profit attributable to shareholders reached 700 million yuan, with a year-on-year increase of 11.38% [1] - The basic earnings per share stood at 0.69 yuan [1]